Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Market outline PART 05: Schizophrenia: Disease overview • Schizophrenia • Medical intervention for treating schizophrenia • Non-medical interventions for treating schizophrenia PART 06: Key clinical trials PART 07: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 08: Market segmentation based on drug-class • First-generation antipsychotic drugs • Second-generation antipsychotic drugs • Third generation antipsychotic drugs PART 09: Geographical segmentation • Market overview based on geography • Schizophrenia therapeutics market in Americas • Schizophrenia therapeutics market in EMEA • Schizophrenia therapeutics market in APAC PART 10: Decision framework PART 11: Drivers and challenges • Market drivers • Market challenges PART 12: Market trends • Rising public interest toward mental health • Increase in use of LAI antipsychotic drugs • Availability of drugs with novel mechanism of action (MoA) PART 13: Vendor landscape • Competitive landscape PART 14: Key vendor analysis • AstraZeneca • Eli Lilly • GlaxoSmithKline • Johnson & Johnson • Other prominent vendors PART 15: Appendix • List of abbreviations List of Exhibits Exhibit 01: Parts of brain affected by schizophrenia Exhibit 02: Prevalence rate of disease Exhibit 03: Reduction in prescription revenue over the years for antipsychotic drugs due to entry of generics Exhibit 04: Types of antipsychotic drugs Exhibit 05: Use of antipsychotic in schizophrenia Exhibit 06: Symptoms of disease Exhibit 07: Non-medical treatment interventions Exhibit 08: Pipeline landscape based on number of molecules Exhibit 09: Key clinical trials in global schizophrenia therapeutics market 2016 Exhibit 10: Snapshot of pipeline trends in global schizophrenia therapeutics market Exhibit 11: Global schizophrenia therapeutics market snapshot Exhibit 12: Global schizophrenia therapeutics market 2016-2021 ($ millions) Exhibit 13: Global schizophrenia therapeutics market: Opportunity analysis Exhibit 14: Five forces analysis Exhibit 15: Market segmentation of global schizophrenia therapeutics market by drug-class Exhibit 16: Global schizophrenia therapeutics market segmentation by drug-class Exhibit 17: Global schizophrenia market revenue by drug-class, 2016-2021 (in $ millions) Exhibit 18: Global schizophrenia first-generation antipsychotic drugs market 2016-2021 ($ millions) Exhibit 19: Global schizophrenia second-generation antipsychotic drugs market 2016-2021 ($ millions) Exhibit 20: Global schizophrenia third-generation antipsychotic drugs market revenue 2016-2021 ($ millions) Exhibit 21: Global schizophrenia therapeutics market share by geography, 2016 and 2021 Exhibit 22: Global schizophrenia therapeutics market revenue by geography, 2016-2021 ($ millions) Exhibit 23: Global schizophrenia therapeutics market share by geography, 2016-2021 Exhibit 24: Market scenario in Americas Exhibit 25: Schizophrenia therapeutics market in Americas 2016-2021 ($ millions) Exhibit 26: Market scenario in EMEA Exhibit 27: Schizophrenia therapeutics market in EMEA 2016-2021 ($ millions) Exhibit 28: Market scenario in APAC Exhibit 29: Schizophrenia therapeutics market in APAC 2016-2021 ($ millions) Exhibit 30: Psychotic symptoms Exhibit 31: Competitive structure analysis of global schizophrenia drugs market 2016 Exhibit 32: AstraZeneca: Strength assessment Exhibit 33: AstraZeneca: Strategy assessment Exhibit 34: AstraZeneca: Opportunity assessment Exhibit 35: AstraZeneca: Revenue garnered by SEROQUEL XR and SEROQUEL IR 2014-2015 ($ millions) Exhibit 36: Eli Lilly: Key highlights Exhibit 37: Eli Lilly: Strength assessment Exhibit 38: Eli Lilly: Strategy assessment Exhibit 39: Eli Lilly: Opportunity assessment Exhibit 40: GlaxoSmithKline: Key highlights Exhibit 41: GlaxoSmithKline: Strength assessment Exhibit 42: GlaxoSmithKline: Strategy assessment Exhibit 43: GlaxoSmithKline: Opportunity assessment Exhibit 44: Johnson & Johnson: Key highlights Exhibit 45: Johnson & Johnson: Strength assessment Exhibit 46: Johnson & Johnson: Strategy assessment Exhibit 47: Johnson & Johnson: Opportunity assessment

AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Alkermes and Bristol-Myers Squibb.